Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis.
Ulcerative colitis
dextran sulfate sodium
imaging
silica particles
Journal
Annals of gastroenterology
ISSN: 1108-7471
Titre abrégé: Ann Gastroenterol
Pays: Greece
ID NLM: 101121847
Informations de publication
Date de publication:
Historique:
received:
30
04
2019
accepted:
18
07
2019
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
9
11
2019
Statut:
ppublish
Résumé
Ulcerative colitis (UC) is a lifelong inflammatory bowel disease characterized by periods of intense colonic inflammation leading to debilitating symptoms. Delivery methods of current UC treatments are suboptimal and associated with side effects. Silica particles are a potential alternative delivery method for UC therapeutics, given their promising drug-loading and safety profiles. However, it is unknown whether silica particles preferably accumulate at sites of colonic inflammation. This study aimed to correlate silica particle accumulation with colonic inflammation in a rat UC model. Albino Wistar rats received 4.5% dextran sulfate sodium (DSS) in drinking water (n=6) for 7 days to induce UC. Control rats (n=6) received drinking water only. UC activity was assessed daily using disease activity index. All rats were orally gavaged with silica particles labeled with Alexa-633 tags on day 9, followed by imaging at 3, 6, and 24 h. Silica particle distribution and accumulation were examined using biophotonic imaging, confocal microscopy and fluorescent spectrophotometry. Rats were killed on day 10, with jejunum, ileum and colon collected for histopathological scoring and quantification of fluorescence. Rats treated with DSS had significantly higher UC disease activity (P=0.033) and colonic histopathological scores (P=0.0087) compared to controls. No statistically significant between-group differences in silica particle accumulation were seen on live imaging or tissue analysis. No correlation was seen between silica particle accumulation and colonic inflammation. However to draw clear conclusions, further research is required to establish the potential of silica particles as a UC-targeted delivery method.
Sections du résumé
BACKGROUND
BACKGROUND
Ulcerative colitis (UC) is a lifelong inflammatory bowel disease characterized by periods of intense colonic inflammation leading to debilitating symptoms. Delivery methods of current UC treatments are suboptimal and associated with side effects. Silica particles are a potential alternative delivery method for UC therapeutics, given their promising drug-loading and safety profiles. However, it is unknown whether silica particles preferably accumulate at sites of colonic inflammation. This study aimed to correlate silica particle accumulation with colonic inflammation in a rat UC model.
METHODS
METHODS
Albino Wistar rats received 4.5% dextran sulfate sodium (DSS) in drinking water (n=6) for 7 days to induce UC. Control rats (n=6) received drinking water only. UC activity was assessed daily using disease activity index. All rats were orally gavaged with silica particles labeled with Alexa-633 tags on day 9, followed by imaging at 3, 6, and 24 h. Silica particle distribution and accumulation were examined using biophotonic imaging, confocal microscopy and fluorescent spectrophotometry. Rats were killed on day 10, with jejunum, ileum and colon collected for histopathological scoring and quantification of fluorescence.
RESULTS
RESULTS
Rats treated with DSS had significantly higher UC disease activity (P=0.033) and colonic histopathological scores (P=0.0087) compared to controls. No statistically significant between-group differences in silica particle accumulation were seen on live imaging or tissue analysis.
CONCLUSIONS
CONCLUSIONS
No correlation was seen between silica particle accumulation and colonic inflammation. However to draw clear conclusions, further research is required to establish the potential of silica particles as a UC-targeted delivery method.
Identifiants
pubmed: 31700235
doi: 10.20524/aog.2019.0411
pii: AnnGastroenterol-32-584
pmc: PMC6826066
doi:
Types de publication
Journal Article
Langues
eng
Pagination
584-592Informations de copyright
Copyright: © Hellenic Society of Gastroenterology.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
N Engl J Med. 1963 Sep 19;269:591-6
pubmed: 14044395
Mediators Inflamm. 2017;2017:4810258
pubmed: 28420941
Scand J Gastroenterol. 1998 Feb;33(2):180-90
pubmed: 9517530
Pharm Res. 2001 Jun;18(6):788-93
pubmed: 11474782
Br J Cancer. 1993 Jul;68(1):41-51
pubmed: 8318419
Inflamm Bowel Dis. 2010 Sep;16(9):1550-6
pubmed: 20803698
Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407
pubmed: 16819502
Nanoscale Res Lett. 2014 Sep 26;9(1):532
pubmed: 25288919
Mol Reprod Dev. 2015 Jul-Aug;82(7-8):518-29
pubmed: 26153368
Dig Dis Sci. 1999 Jul;44(7):1458-75
pubmed: 10489934
Oman Med J. 2010 Apr;25(2):79-87
pubmed: 22125706
Aliment Pharmacol Ther. 2000 Feb;14(2):155-61
pubmed: 10651655
Gut. 1993 Sep;34(9):1177-81
pubmed: 8406149
Gut. 1989 Apr;30(4):455-9
pubmed: 2714679
Curr Protoc Immunol. 2014 Feb 04;104:Unit 15.25.
pubmed: 24510619
Gastroenterology. 2005 Aug;129(2):550-64
pubmed: 16083712
Scand J Gastroenterol. 1978;13(7):833-7
pubmed: 364626
Expert Rev Gastroenterol Hepatol. 2009 Jun;3(3):219-29
pubmed: 19485804
Clin Colon Rectal Surg. 2004 Feb;17(1):7-19
pubmed: 20011280
Therap Adv Gastroenterol. 2009 Mar;2(2):99-108
pubmed: 21180538
J Surg Res. 2007 Jun 1;140(1):12-9
pubmed: 17418867
Nanomaterials (Basel). 2017 Jul 22;7(7):null
pubmed: 28737672
J Crohns Colitis. 2018 Jan 24;12(2):217-229
pubmed: 28961808
Small. 2009 Apr;5(7):846-53
pubmed: 19288475
Dig Dis Sci. 2012 Mar;57(3):713-9
pubmed: 22038505
Mol Cell Biochem. 2013 Feb;374(1-2):1-11
pubmed: 23271629
Int J Pharm. 2016 Jul 25;509(1-2):118-122
pubmed: 27231121
BMJ Qual Saf. 2011 Dec;20(12):1027-34
pubmed: 21690248